Evidence map›Paper›PMID 28202756›Full record

ArticleJournal of virology2017

Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.

Eden P Go, Haitao Ding, Shijian Zhang, Rajesh P Ringe, Nathan Nicely, David Hua, Robert T Steinbock, Michael Golabek, James Alin, S Munir Alam and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Eden P GoDepartment of Chemistry, University of Kansas, Lawrence, Kansas, USA.
Haitao DingDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Shijian ZhangDepartment of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA.
Rajesh P RingeDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Nathan NicelyDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
David HuaDepartment of Chemistry, University of Kansas, Lawrence, Kansas, USA.
Robert T SteinbockDepartment of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA.
Michael GolabekDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
James AlinDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Albert CupoDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
John C KappesDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
John P MooreDepartment of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
Joseph G SodroskiDepartment of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA.
Heather DesaireDepartment of Chemistry, University of Kansas, Lawrence, Kansas, USA hdesaire@ku.edu.
Cornell University · USDuke Medical Center · USUniversity of Kansas · USDana-Farber Cancer Institute · USUniversity of Alabama at Birmingham · USHarvard University · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2006 to 2011
$290.5M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
Structural studies of native-like SOSIP trimersP01AI110657 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2015 to 2024
$35.4M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2M
HIV-1 ENVELOPE GLYCOPROTEINSR37AI024755 · NIAID · DANA-FARBER CANCER INSTITUTE · PI SODROSKI, JOSEPH G · 1996 to 2015
$11.6M
Generating Native Env Glycosylation in HIV Vaccine CandidatesR01AI125093 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DESAIRE, HEATHER R · 2016 to 2019
$2.7M
Development of a rapid glycosylation profiling system using mass spectrometry datR01GM103547 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI DESAIRE, HEATHER R · 2012 to 2017
$1.8M
Characterization of PTMs on Env to support HIV vaccine developmentR01AI094797 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DESAIRE, HEATHER R · 2012 to 2015
$1.4M
Production & Crystallization of Membrane Protein for 3D StructureR01GM095639 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DELUCAS, LAWRENCE J · 2010 to 2013
$1.2M
NIAID NIH HHS P01 AI110657NIAID NIH HHS P30 AI027767NIAID NIH HHS R01 AI094797NIAID NIH HHS R01 AI125093NIAID NIH HHS R37 AI024755NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI100645NIGMS NIH HHS P01 GM056550NIGMS NIH HHS R01 GM095639NIGMS NIH HHS R01 GM103547
6 · The paper itself

Abstract

HIV-1 envelope glycoprotein (Env) glycosylation is important because individual glycans are components of multiple broadly neutralizing antibody epitopes, while shielding other sites that might otherwise be immunogenic. The glycosylation on Env is influenced by a variety of factors, including the genotype of the protein, the cell line used for its expression, and the details of the construct design. Here, we used a mass spectrometry (MS)-based approach to map the complete glycosylation profile at every site in multiple HIV-1 Env trimers, accomplishing two goals. (i) We determined which glycosylation sites contain conserved glycan profiles across many trimeric Envs. (ii) We identified the variables that impact Env's glycosylation profile at sites with divergent glycosylation. Over half of the gp120 glycosylation sites on 11 different trimeric Envs have a conserved glycan profile, indicating that a native consensus glycosylation profile does indeed exist among trimers. We showed that some soluble gp120s and gp140s exhibit highly divergent glycosylation profiles compared to trimeric Env. We also assessed the impact of several variables on Env glycosylation: truncating the full-length Env; producing Env, instead of the more virologically relevant T lymphocytes, in CHO cells; and purifying Env with different chromatographic platforms, including nickel-nitrilotriacetic acid (Ni-NTA), 2G12, and PGT151 affinity. This report provides the first consensus glycosylation profile of Env trimers, which should serve as a useful benchmark for HIV-1 vaccine developers. This report also defines the sites where glycosylation may be impacted when Env trimers are truncated or produced in CHO cells.

Indexed as

AIDS VaccinesAmino Acid SequenceAnimalsAntibodies, NeutralizingBenchmarkingCHO CellsCricetinaeCricetulusenv Gene Products, Human Immunodeficiency VirusEpitopesGlycosylationHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41Immune EvasionAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41Envglycopeptideshuman immunodeficiency virus

Identifiers

PMID28202756
PMCPMC5391476
OpenAlexW2588060834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.